Hong Kong Stock Movement: CLOUDBREAK-B falls 17.51%, facing dual pressure from judicial preservation and lifting of restrictions on stock price

Hong Kong Stock Movement CLOUDBREAK-B fell by 17.51%. Based on recent key news: On January 6, CLOUDBREAK's Guangzhou branch received a court notice for judicial preservation, affecting the stock price. The court, at the request of Cedar Wealth, implemented judicial preservation on CLOUDBREAK's Guangzhou bank account, involving an amount of approximately RMB 2.55 million. This event raised market concerns, leading to a decline in stock price. Source: Zhitong Finance On January 5, CLOUDBREAK's cornerstone investors were released from lock-up, putting pressure on the stock price. Fucheng Holdings Limited extended the lock-up period to July 2, but the number of shares released was approximately 17.72 million, raising market concerns about selling pressure after the lock-up. Source: Zhitong Finance On January 6, CLOUDBREAK successfully submitted a clinical trial application for a new drug, failing to boost the stock price. Although the CBT-009 clinical trial application marks an important milestone, market attention to the judicial preservation event overshadowed this positive news. Source: Zhitong Finance. The industry faces judicial risks, with significant capital outflows. Stocks with High Trading Volume in the Industry Bohui Biotechnology rose by 8.57%. Based on recent key news: On January 9, Bohui Biotechnology recorded a large transaction with a trading volume of HKD 444 million. This transaction was non-automated matching, indicating strong market interest in the stock, driving the price up. No other significant news recently. No other significant news recently. The Hong Kong stock market has been active recently, with noticeable capital inflows. BeiGene fell by 3.36%. Based on recent news: On January 6, BeiGene announced that its self-developed Class 1 new drug, the novel BCL2 inhibitor Baiyueda® (sotuximab), received conditional approval from the National Medical Products Administration for the treatment of patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), as well as patients with relapsed or refractory mantle cell lymphoma (MCL). This news had a positive impact on the company's stock price, but the market response was complex, leading to price fluctuations. On January 7, BeiGene announced that its board granted a total of 53,322 restricted stock units of American Depositary Shares to 155 grantees under the 2016 option and incentive plan, equivalent to 693,200 shares, accounting for approximately 0.04% of the company's total issued shares. This news may raise market concerns about equity dilution, leading to a decline in stock price. On January 8, CMB International released a weekly report on the pharmaceutical industry, noting that the Hong Kong pharmaceutical sector performed well and suggested focusing on leading companies in innovative drugs and the CXO segment. Although BeiGene was recommended as one of the focus stocks, overall market sentiment and capital flow negatively impacted the stock price. The pharmaceutical sector performed well, focusing on innovative drugs and CXO. Innovent Biologics fell by 0.17%. Based on recent key news: On January 2, Morgan Stanley increased its holdings in Innovent Biologics by 3.17 million shares, showing market confidence in its future growth. After the increase, the holding ratio reached 5.16%, with the stock price stabilizing at HKD 78.4477 Source: Zhitong Finance On January 6, 2023, Innovent Biologics' GLP-1 therapy, Ma Shidu Peptide, stood out in market competition, with Nomura Securities maintaining a "Buy" rating and a target price of HKD 105.80. Source: Nomura Securities On January 6, 2023, Innovent Biologics reduced overseas supply chain risks through domestic substitution, enhancing supply chain resilience. Source: Yicai Global, pharmaceutical industry growth differentiation, driven by chronic diseases. Stocks ranked at the top of the industry market capitalization Kangfang Biologics fell 0.08%. Based on recent key news: On January 7, 2023, Kangfang Biologics experienced large transactions in the Hong Kong market, with a transaction amount exceeding HKD 22.47 million, indicating high market attention on the stock, which may affect price volatility. On January 6, 2023, Kangfang Biologics announced that its PD-1/VEGF bispecific antibody ivonescimab received label update approval from the National Medical Products Administration of China, a milestone event that enhances the company's position in the Chinese market. On January 7, 2023, HSBC analysts stated that the global expansion strategy of Chinese pharmaceutical companies is shifting towards comprehensive clinical development and commercialization, with Kangfang Biologics being considered one of the companies with a strong product line, potentially driving its valuation up. Innovation support policies in the pharmaceutical industry are strengthening